BioCentury | Feb 11, 2019
Distillery Therapeutics

Infectious disease

...of the compound in mouse models with chronic, severe Buruli ulcers. Qurient Co. Ltd. and Infectex Ltd....
BioCentury | Jul 10, 2018
Distillery Therapeutics

Infectious disease

...include optimizing and testing the inhibitor in additional models of TB. Qurient Co. Ltd. and Infectex Ltd....
BioCentury | Apr 21, 2017
Clinical News

SQ109: Ph IIb/III data

...tolerated. In 2006, the NIH granted Sequella exclusive, worldwide rights to SQ109 to treat TB. Infectex...
...April 10, 2006 & May 2, 2011 ). Infectex is a portfolio company of Maxwell. Infectex Ltd....
...tuberculosis (MDR-TB) Endpoint: Clearance of lung bacteria and safety Status: Phase IIb/III data Milestone: NA Chris Lieu SQ109 Infectex Ltd. National...
BioCentury | Feb 17, 2014
Company News

Infectex, Qurient deal

...Qurient granted Infectex exclusive rights to develop and commercialize preclinical tuberculosis compound Q203 in Russia, Armenia...
...compound Q203 in Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan and Ukraine. Infectex...
...deal could be valued at over $100 million. Qurient declined to disclose additional details, and Infectex...
Items per page:
1 - 4 of 4
BioCentury | Feb 11, 2019
Distillery Therapeutics

Infectious disease

...of the compound in mouse models with chronic, severe Buruli ulcers. Qurient Co. Ltd. and Infectex Ltd....
BioCentury | Jul 10, 2018
Distillery Therapeutics

Infectious disease

...include optimizing and testing the inhibitor in additional models of TB. Qurient Co. Ltd. and Infectex Ltd....
BioCentury | Apr 21, 2017
Clinical News

SQ109: Ph IIb/III data

...tolerated. In 2006, the NIH granted Sequella exclusive, worldwide rights to SQ109 to treat TB. Infectex...
...April 10, 2006 & May 2, 2011 ). Infectex is a portfolio company of Maxwell. Infectex Ltd....
...tuberculosis (MDR-TB) Endpoint: Clearance of lung bacteria and safety Status: Phase IIb/III data Milestone: NA Chris Lieu SQ109 Infectex Ltd. National...
BioCentury | Feb 17, 2014
Company News

Infectex, Qurient deal

...Qurient granted Infectex exclusive rights to develop and commercialize preclinical tuberculosis compound Q203 in Russia, Armenia...
...compound Q203 in Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan and Ukraine. Infectex...
...deal could be valued at over $100 million. Qurient declined to disclose additional details, and Infectex...
Items per page:
1 - 4 of 4